Dr. Vanesa Gregorc

Specialised Oncologist

Thoracic Neoplasm – Lung cancer – 
Pleural Mesothelioma
 – Thymus cancer – Immuno-oncology

“Knowledge and Information are tools for a better treatment. I have great interest for innovative and personalised therapies, for the quality of life of patients and the educational and informational support they receive as it leads to a greater comprehension of the diagnostic and therapeutic choices they make."
– Dr.ssa Vanesa Gregorc –

IRCCS San Raffaele Hospital in Milan (since 2001)

– Thoracic Oncologist, Head-Neck and Melanoma Area Coordinator at the San Raffaele Hospital in Milan.

– Group leader at the Research Division of Molecular Oncology at the San Raffaele Hospital in Milan

– General Secretary of the Working Lung Group “Alleanza Contro il Cancro” and Member of the Working Groups Melanoma, Immunology and Genomics.

– Contract Professor of the Faculty of Medicine and Surgery at the Vita-Salute San Raffaele University for the MD International Program-Course Oncology.

Clinical and research activity

Doctor Gregorc performs clinical and research activities on thoracic neoplasms with a focus on identifying biomarkers to choose targeted therapies tailored to the need of a patient.

She has participated in the development of various innovative treatments such as antitumor drugs today available in clinical practices: EGFR inhibitors (afatinib, erlotinib, gefitinib) and ALK inhibitors (crizotinib, alectinib, brigatinib, lorlatinib), antivascular and antiangiogenic (nintedanib, ramucirumab, bevacizumab) and immunotherapeutic treatments (atezolizumab, nivolumab, pembrolizumab).

She has also been contributing, for more than 20 years, to the development of various chemotherapeutic drugs for the treatment of solid tumours, specifically lung and pleural mesothelioma tumours.

Vanesa Gregorc is also coordinator and initiator of various research projects not associated with the pharmaceutical sector: studies on experimental treatments, new diagnostic-therapeutic approaches for pulmonary carcinoma and malignant pleural mesothelioma.

She promoted and completed a national study on the advanced stage of pulmonary carcinoma to explore and confirm the role of a method of predicting the response of a treatment using proteomic. In 2013 her project was selected to be presented at the American congress ASCO (American Society of Clinical Oncology) and published in the renowned magazine JNCI (Journal of the National Cancer Institute). The study was also inserted in the NCI (National Cancer Institute) guidelines for the choice of line II treatment for pulmonary carcinoma.

Doctor Gregorc has also contributed to the study of the anti-tumour drug NGR-TNFalfa from its insertion in the body to the treatment of pleural mesothelioma. The drug is currently being evaluated by EMA (European Medicines Agency) to be registered in Europe, and studied to treat microcytoma in association with anthracyclines with promising results.

Doctor Gregorc has also won different Grants for research projects from AIRC (the Italian Research Association against Cancer), the Ministry of Health and the Umbra association “Lotta Contro il Cancro”.

Teaching Activity

– Contract Professor of the Faculty of Medicine and Surgery at the Vita-Salute San Raffaele University for the MD International Program-Course Oncology.

– Professor at the European School of Oncology (ESO)-Master class

Ministry of Health collaboration

Member of the commission for the development of a National Health Research Program as well Supervisor of Research and Scientific Institution Centres in Italy (From 2011 to 2013).

Since 2016 she has acted as secretary for the Alliance Against Cancer, an oncological network created to bring together the main Italian Scientific Research Institutes, and supported by the Ministry of Health.

Other Activities

Co-founder of the online platform for second medical opinions from medical experts, Ultraspecialisti.com.

Creator and promoter of websites dedicated to tumours: LungCancers.eu, Tumorealpolmone.it, Tumoritestaecollo.it

Founder member of Lucenetwork, the Italian community for the development of clinical studies against thoracic neoplasms.

Education and training

General Pathology, Medicine and Surgery Laboratory at the University of Perugia (1993-5)

Medical Degree at the University of Perugia, Faculty of Medicine and Surgery (1997)

Workshop ACCR/ASCO/FECS: research Methodology (2001)

Specialisation in Oncology at the University of Perugia (2002)

Training and experiential course at The Mont Sinai School of Medicine in New York (2003).

Registered with the Certified Medical Association

Registered with the Certified Medical Association “Albo dei Medici” in Milan, n. 39190.

Medical Career

Since 2001 she works at the San Raffaele Hospital in Milan as Oncologist and has covered various roles:
– Coordinator of the Oncological Thoracic group since 2003
– Coordinator of the Melanoma division since 2013
– Since 2015 Coordinator of the Thoracic, Melanoma, Head-Neck Division

Multidisciplinary activities and Scientific Membership

– Member and Coordinator of the Disease Unit of thoracic neoplasm and author of PDTA (Assistance in diagnostic and therapeutic path) on pulmonary tumours at the San Raffaele Hospital.

– Member of the Disease Unit of Melanoma at the San Raffaele Hospital in Milan.

– Member of the Disease Unit of the Head-Neck Division at the San Raffaele Hospital in Milan.

– Coordinator of Homecare assistance for patients diagnosed with tumours under the care of Umbra Association “Lotta contro il Cancro”(1998-2001).

– Member of the Scientific Committee “San Raffaele Scientific Retreat”.

– Member of the San Raffaele Hospital committee for patent assessment.

– Member of the “Moses Project” Committee of ESMO (European Society for Medical Oncology)

– Member of ASCO (American Society of Clinical Oncology)

– Member of IASLC International Association for the Study of Lung Cancer.

– Member of the European Society for Medical Oncology, ESMO.

– Member of AIOM (Italian Society for Medical Oncology).

– General Secretary and Vice President of Films Aulmni Club.


Italian – English – Croatian – Slovenian – German

Treated cancer diseases

Lung cancer
Pleural Mesothelioma
Targeted Therapy
Thymus cancer

San Raffaele Hospital
Oncology Division
Via Olgettina 60
20132 Milan, Italy

Per prenotare una visita ambulatoriale in libera professione: +39 02 26436560

Per prenotare una visita ambulatoriale tramite SSN: +39 02 26432643

Casa di Cura La Madonnina (Gruppo SanDonato)
Via Quadronno, 29
20122 – Milan, Italy

Per prenotare una visita ambulatoriale: +39 02 58395555

Online Medical Consultation with Dr. Gregorc

Dr. Gregorc awarded by the San Raffaele Hospital

Dr. Gregorc awarded by the San Raffaele Hospital

Best Clinical Research Paper 2018 Dr. Gregorc awarded by the San Raffaele Hospital Article by Diego ErrichettiSocial Media & PRUltraspecialisti.com…

Leggi tutto l'articolo
Adjuvant therapy for the treatment of Melanoma

Adjuvant therapy for the treatment of Melanoma

Adjuvant therapy for the treatment of Melanoma. The results of new studies to eliminate recurrences Article by Dr. Alessandra BulottaOncologist…

Leggi tutto l'articolo
Teleconsultation? Today it’s Possible. The best medical care and diagnostic solutions in 5 days.

Teleconsultation? Today it’s Possible. The best medical care and diagnostic solutions in 5 days.

Teleconsultation? Today it’s Possible. The best medical care and diagnostic solutions in 5 days. Dr. Vanesa GregorcOncologist specialized in thoracic…

Leggi tutto l'articolo

Author and co-author of more than 80 scientific publications selected by Pubmed and available on Researchgate.

Has participated to more than 200 educational lectures, presentations at national and international events.

Her articles are published in internationally renowned scientific magazines such as Clinical Cancer Research (USA), Cancer, Journal of Clinical Oncology (USA), Journal of the National Cancer Institute (UK), Lung Cancer, Annals of Oncology (UK), British Journal of Cancer and Lancet Oncology (UK).

Editor of scientific papers for renowned scientific magazines such as Lung Cancer (USA), Journal of Clinical Oncology (USA), Journal of Thoracic Oncology (USA), Journal of the National Cancer Institute (UK) etc.


Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study.
Gobbini E, Chiari R, Pizzutillo P, Bordi P, Ghilardi L, Pilotto S, Osman G, Cappuzzo F, Cecere F, Riccardi F, Scotti V, Martelli O, Borra G, Maiello E, Rossi A, Graziano P, Gregorc V, Casartelli C, Sergi C, Del Conte A, Delmonte A, Bareggi C, Cortinovis D, Rizzo P, Tabbò F, Rossi G, Bria E, Galetta D, Tiseo M, Di Maio M, Novello S.
Clin Transl Oncol. 2019 Oct 19. doi: 10.1007/s12094-019-02222-8.

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators.
Lancet Oncol. 2019 Oct 4. pii: S1470-2045(19)30634-5. doi: 10.1016/S1470-2045(19)30634-5.

How to obtain severe hypoglycemia without causing brain or cardiac damage.
Baiardo Redaelli M, Zangrillo A, Gregorc V, Ciceri F, Dagna L, Tshomba Y, Navalesi P, Landoni G.
Med Hypotheses. 2019 Sep;130:109276. doi: 10.1016/j.mehy.2019.109276.

Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I, Magliacane G, Lazzari C, Grassini G, Brunetto E, Dal Cin E, Girlando S, Medicina D, Smart CE, Bulotta A, Gregorc V, Pecciarini L, Doglioni C, Cangi MG.
Lung Cancer. 2019 Aug;134:225-232. doi: 10.1016/j.lungcan.2019.06.010.

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.
Capelletto E, Migliorino MR, Morabito A, Chiari R, Grossi F, Tiseo M, Costanzo FD, Delmonte A, Romano G, Galetta D, Scotti V, Gregorc V, Pisconti S, Ceresoli GL, Del Conte A, Ciuffreda L, Colantonio I, Bria E, Ricciardi S, Manzo A, Metro G, Morelli AM, Critelli R, Pacchiana MV, Stura I, Migliaretti G, Novello S.
Lung Cancer. 2019 Aug;134:210-217. doi: 10.1016/j.lungcan.2019.06.028.

PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review.
Mirabile A, Brioschi E, Ducceschi M, Piva S, Lazzari C, Bulotta A, Viganò MG, Petrella G, Gianni L, Gregorc V.
Cancers (Basel). 2019 Mar 1;11(3). pii: E296. doi: 10.3390/cancers11030296.

Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer.
Lazzari C, Gregorc V, Bulotta A, Dottore A, Altavilla G, Santarpia M.
Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S329-S333. doi: 10.21037/tlcr.2018.12.02.

Combined exosomal RNA and circulating tumor DNA for epidermal growth factor mutation detection in non-small cell lung cancer.
Lazzari C, Gregorc V, Cangi MG, Giovannetti E, Bulotta A, Santarpia M.
J Thorac Dis. 2018 Nov;10(Suppl 33):S4023-S4027. doi: 10.21037/jtd.2018.10.17.

Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis.
Garassino MC, Kawaguchi T, Gregorc V, Rulli E, Ando M, Marsoni S, Isa SI, Novello S, Farina G, Barni S, Torri V, Cinquini M.
ESMO Open. 2018 Nov 1;3(6):e000327. doi: 10.1136/esmoopen-2018-000327. eCollection 2018.

Invasive Pulmonary Aspergillosis Complicated by Carbapenem-Resistant Pseudomonas aeruginosa Infection During Pembrolizumab Immunotherapy for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature.
Oltolini C, Ripa M, Andolina A, Brioschi E, Cilla M, Petrella G, Gregorc V, Castiglioni B, Tassan Din C, Scarpellini P.
Mycopathologia. 2019 Feb;184(1):181-185. doi: 10.1007/s11046-018-0291-4. Epub 2018 Aug 13.

NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.
Gregorc V, Cavina R, Novello S, Grossi F, Lazzari C, Capelletto E, Genova C, Salini G, Lambiase A, Santoro A.
Oncologist. 2018 Oct;23(10):1133-e112. doi: 10.1634/theoncologist.2018-0292.

Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies.
Petrelli F, Lazzari C, Ardito R, Borgonovo K, Bulotta A, Conti B, Cabiddu M, Capitanio JF, Brighenti M, Ghilardi M, Gianni L, Barni S, Gregorc V.
PLoS One. 2018 Jul 27;13(7):e0201425. doi: 10.1371/journal.pone.0201425. eCollection 2018.

Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer.
Gregorc V, Lazzari C, Karachaliou N, Rosell R, Santarpia M.
Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S165-S170. doi: 10.21037/tlcr.2018.03.19.

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Gregorc V, Gaafar RM, Favaretto A, Grossi F, Jassem J, Polychronis A, Bidoli P, Tiseo M, Shah R, Taylor P, Novello S, Muzio A, Bearz A, Greillier L, Fontana F, Salini G, Lambiase A, O’Brien M.
Lancet Oncol. 2018 Jun;19(6):799-811. doi: 10.1016/S1470-2045(18)30193-1.

Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
Lazzari C, Karachaliou N, Bulotta A, Viganó M, Mirabile A, Brioschi E, Santarpia M, Gianni L, Rosell R, Gregorc V.
Ther Adv Med Oncol. 2018 Apr 6;10:1758835918762094. doi: 10.1177/1758835918762094. eCollection 2018. Review.

Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.
Metro G, Passaro A, Lo Russo G, Bonanno L, Giusti R, Gregorc V, Capelletto E, Martelli O, Cecere FL, Giannarelli D, Luciani A, Bearz A, Tuzi A, Scotti V, Tonini G, Galetta D, Carta A, Soto Parra H, Rebonato A, Morabito A, Chiari R.
Future Oncol. 2018 Feb;14(4):353-361. doi: 10.2217/fon-2017-0441.

A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.
Deutsch E, Moyal EC, Gregorc V, Zucali PA, Menard J, Soria JC, Kloos I, Hsu J, Luan Y, Liu E, Vezan R, Graef T, Rivera S.
Oncotarget. 2016 Dec 24;8(34):56199-56209. doi: 10.18632/oncotarget.14147. eCollection 2017 Aug 22.

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.
Gobbini E, Galetta D, Tiseo M, Graziano P, Rossi A, Bria E, Di Maio M, Rossi G, Gregorc V, Riccardi F, Scotti V, Ceribelli A, Buffoni L, Delmonte A, Franchina T, Migliorino MR, Cortinovis D, Pisconti S, Bordi P, Catino A, Maiello E, Arizio F, Novello S; other Co-Authors.
Lung Cancer. 2017 Sep;111:30-37. doi: 10.1016/j.lungcan.2017.06.009.

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.
Lazzari C, Karachaliou N, Gregorc V, Bulotta A, Gonzalez-Cao M, Verlicchi A, Altavilla G, Rosell R, Santarpia M.
Expert Rev Respir Med. 2017 Jun;11(6):469-479. doi: 10.1080/17476348.2017.1326822.

Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer.
Lazzari C, Bulotta A, Ducceschi M, Viganò MG, Brioschi E, Corti F, Gianni L, Gregorc V.
Front Med (Lausanne). 2017 Jan 23;4:4. doi: 10.3389/fmed.2017.00004. eCollection 2017.

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.
Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF; EMPHASIS-lung Collaborative Group.
J Thorac Oncol. 2017 Apr;12(4):752-762. doi: 10.1016/j.jtho.2016.12.017.

New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group.
Cortinovis D, Gregorc V, Migliorino MR, Abate MI, Manzo A, Malapelle U, Morabito A; Italian Lung Cancer Working Group.
Crit Rev Oncol Hematol. 2017 Jan;109:35-41. doi: 10.1016/j.critrevonc.2016.11.015.

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
Tartarone A, Lerose R, Lazzari C, Gregorc V, Aieta M.
Med Oncol. 2014 Aug;31(8):78. doi: 10.1007/s12032-014-0078-5.

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
Gregorc V, Novello S, Lazzari C, Barni S, Aieta M, Mencoboni M, Grossi F, De Pas T, de Marinis F, Bearz A, Floriani I, Torri V, Bulotta A, Cattaneo A, Grigorieva J, Tsypin M, Roder J, Doglioni C, Levra MG, Petrelli F, Foti S, Viganò M, Bachi A, Roder H.
Lancet Oncol. 2014 Jun;15(7):713-21. doi: 10.1016/S1470-2045(14)70162-7.

Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
Tartarone A, Lazzari C, Lerose R, Conteduca V, Improta G, Zupa A, Bulotta A, Aieta M, Gregorc V.
Lung Cancer. 2013 Sep;81(3):328-336. doi: 10.1016/j.lungcan.2013.05.020.

Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.
Corti A, Curnis F, Rossoni G, Marcucci F, Gregorc V.
BioDrugs. 2013 Dec;27(6):591-603. doi: 10.1007/s40259-013-0048-z.

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience.
Bearz A, Talamini R, Rossoni G, Santo A, de Pangher V, Fasola G, Rosetti F, Favaretto A, Gregorc V, Berretta M, Santarossa S, Berto E, Tirelli U.
BMC Res Notes. 2012 Sep 3;5:482. doi: 10.1186/1756-0500-5-482.

SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors.
Milan E, Lazzari C, Anand S, Floriani I, Torri V, Sorlini C, Gregorc V, Bachi A.
J Proteomics. 2012 Dec 5;76 Spec No.:91-101. doi: 10.1016/j.jprot.2012.06.022.

Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy.
Sprowl JA, Gregorc V, Lazzari C, Mathijssen RH, Loos WJ, Sparreboom A.
Clin Pharmacol Ther. 2012 Jun;91(6):1022-6. doi: 10.1038/clpt.2011.330.

Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors.
Lazzari C, Spreafico A, Bachi A, Roder H, Floriani I, Garavaglia D, Cattaneo A, Grigorieva J, Viganò MG, Sorlini C, Ghio D, Tsypin M, Bulotta A, Bergamaschi L, Gregorc V.
J Thorac Oncol. 2012 Jan;7(1):40-8. doi: 10.1097/JTO.0b013e3182307f17.

Combined treatment of non-small cell lung cancer with synchronous brain metastases: a single center experience.
Melloni G, Bandiera A, Gregorc V, Carretta A, Ciriaco P, Viganò M, Franzin A, Bolognesi A, Picozzi P, Zannini P.
J Cardiovasc Surg (Torino). 2011 Aug;52(4):613-9.

Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors.
Gregorc V, De Braud FG, De Pas TM, Scalamogna R, Citterio G, Milani A, Boselli S, Catania C, Donadoni G, Rossoni G, Ghio D, Spitaleri G, Ammannati C, Colombi S, Caligaris-Cappio F, Lambiase A, Bordignon C.
Clin Cancer Res. 2011 Apr 1;17(7):1964-72. doi: 10.1158/1078-0432.CCR-

Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer.
Spitaleri G, Delmonte A, Toffalorio F, De Pas TM, Gregorc V.
J Thorac Oncol. 2010 May;5(5):752-4. doi: 10.1097/JTO.0b013e3181d6b8a1.

Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
Gregorc V, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM, Zilembo N, De Vincenzo F, Simonelli M, Rossoni G, Spreafico A, Grazia Viganò M, Fontana F, De Braud FG, Bajetta E, Caligaris-Cappio F, Bruzzi P, Lambiase A, Bordignon C.
J Clin Oncol. 2010 May 20;28(15):2604-11. doi: 10.1200/JCO.2009.27.3649.

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
Gregorc V, Citterio G, Vitali G, Spreafico A, Scifo P, Borri A, Donadoni G, Rossoni G, Corti A, Caligaris-Cappio F, Del Maschio A, Esposito A, De Cobelli F, Dell’Acqua F, Troysi A, Bruzzi P, Lambiase A, Bordignon C.
Eur J Cancer. 2010 Jan;46(1):198-206. doi: 10.1016/j.ejca.2009.10.005.

Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies.
Giovannini M, Gregorc V, Belli C, Roca E, Lazzari C, Viganò MG, Serafico A, Villa E.
J Oncol. 2009;2009:849051. doi: 10.1155/2009/849051.

Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours.
Gregorc V, Santoro A, Bennicelli E, Punt CJ, Citterio G, Timmer-Bonte JN, Caligaris Cappio F, Lambiase A, Bordignon C, van Herpen CM.
Br J Cancer. 2009 Jul 21;101(2):219-24. doi: 10.1038/sj.bjc.6605162.

Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.
Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Di Carlo L, Semeraro A, Daddi G, Darwish S, Stocchi L, Tofanetti FR, Bellezza G, Sidoni A, Tognellini R, Crinò L, Tonato M.
Tumori. 2008 May-Jun;94(3):398-405.

Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case?
Giovannini M, Belli C, Villa E, Gregorc V.
J Thorac Oncol. 2008 Jun;3(6):684-5. doi: 10.1097/JTO.0b013e3181757aec.

Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Piattoni S, Di Carlo L, Semeraro A, Darwish S, Tofanetti FR, Stocchi L, Mihaylova Z, Bellezza G, Del Sordo R, Daddi G, Crinò L, Tonato M.
J Thorac Oncol. 2008 Apr;3(4):365-73. doi: 10.1097/JTO.0b013e318168c7d0.

Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib.
Gregorc V, Hidalgo M, Spreafico A, Cusatis G, Ludovini V, Ingersoll RG, Marsh S, Steinberg SM, Viganò MG, Ghio D, Villa E, Sparreboom A, Baker SD.
Clin Pharmacol Ther. 2008 Mar;83(3):477-84.

Endothelial growth factor receptor inhibition after radiotherapy.
Giovannini M, Gregorc V, Viganò MG, Spreafico A, Ghio D, Dell’Oca I, Bolognesi A, Villa E.
J Thorac Oncol. 2007 Jul;2(7):662.

Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
Gregorc V, Spreafico A, Floriani I, Colombo B, Ludovini V, Pistola L, Bellezza G, Viganò MG, Villa E, Corti A.
Cancer. 2007 Aug 15;110(4):845-53.

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA Jr, Carbone DP.
J Natl Cancer Inst. 2007 Jun 6;99(11):838-46.

Role of computed tomography and [18F] fluorodeoxyglucose positron emission tomography image fusion in conformal radiotherapy of non-small cell lung cancer: a comparison with standard techniques with and without elective nodal irradiation.
Ceresoli GL, Cattaneo GM, Castellone P, Rizzos G, Landoni C, Gregorc V, Calandrino R, Villa E, Messa C, Santoro A, Fazio F.
Tumori. 2007 Jan-Feb;93(1):88-96.

Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.
Gridelli C, Kaukel E, Gregorc V, Migliorino MR, Müller TR, Manegold C, Favaretto A, Martoni A, Caffo O, Schmittel A, Rossi A, Russo F, Peterson P, Muñoz M, Reck M.
J Thorac Oncol. 2007 Mar;2(3):221-9.

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD.
J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.

Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
Messa C, Ceresoli GL, Rizzo G, Artioli D, Cattaneo M, Castellone P, Gregorc V, Picchio M, Landoni C, Fazio F.
Q J Nucl Med Mol Imaging. 2005 Sep;49(3):259-66.

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA Jr, Hirsch FR.
J Clin Oncol. 2005 Aug 1;23(22):5007-18.

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M.
J Natl Cancer Inst. 2005 May 4;97(9):643-55.

Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer.
Gregorc V, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, Ludovini V, Pistola L, Mihaylova Z, Tofanetti FR, Ferraldeschi M, Torri V, Cappuzzo F, Crinò L, Tonato M, Villa E.
Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6006-12.

Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Ludovini V, Gregorc V, Pistola L, Mihaylova Z, Floriani I, Darwish S, Stracci F, Tofanetti FR, Ferraldeschi M, Di Carlo L, Ragusa M, Daddi G, Tonato M.
Lung Cancer. 2004 Oct;46(1):77-85.

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crinò L.
J Natl Cancer Inst. 2004 Aug 4;96(15):1133-41.

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.
Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crinò L, Villa E.
Ann Oncol. 2004 Jul;15(7):1042-7.

Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
Ceresoli GL, Gregorc V, Cordio S, Bencardino KB, Schipani S, Cozzarini C, Bordonaro R, Villa E.
Lung Cancer. 2004 May;44(2):231-9.

Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC).
Cappuzzo F, Bartolini S, Ceresoli GL, Tamberi S, Spreafico A, Lombardo L, Gregorc V, Toschi L, Calandri C, Villa E, Crinò L.
Br J Cancer. 2004 Jan 12;90(1):82-6.

The clinical relevance of Bcl-2, Rb and p53 expression in advanced non-small cell lung cancer.
Gregorc V, Darwish S, Ludovini V, Pistola L, De Angelis V, Mihaylova Z, Bellezza G, Sidoni A, Cavaliere A, Bucciarelli E, Massaro G, Tonato M.
Lung Cancer. 2003 Dec;42(3):275-81.

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
Cappuzzo F, Gregorc V, Rossi E, Cancellieri A, Magrini E, Paties CT, Ceresoli G, Lombardo L, Bartolini S, Calandri C, de Rosa M, Villa E, Crino L.
J Clin Oncol. 2003 Jul 15;21(14):2658-63.

Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study.
Cappuzzo F, Selvaggi G, Gregorc V, Mazzoni F, Betti M, Rita Migliorino M, Novello S, Maestri A, De Marinis F, Darwish S, De Angelis V, Nelli F, Bartolini S, Scagliotti GV, Tonato M, Crinò L.
Cancer. 2003 Jul 1;98(1):128-34.

Mediastinal follicular dendritic cell sarcoma.
Ceresoli GL, Zucchinelli P, Ponzoni M, Gregorc V, Bencardino K, Paties CT.
Haematologica. 2003 Feb;88(2):ECR04.

Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Gregorc V, Ludovini V, Pistola L, Darwish S, Floriani I, Bellezza G, Sidoni A, Cavaliere A, Scheibel M, De Angelis V, Bucciarelli E, Tonato M.
Lung Cancer. 2003 Jan;39(1):41-8.

Biological prognostic factors for early stage completely resected non-small cell lung cancer.
Cagini L, Monacelli M, Giustozzi G, Moggi L, Bellezza G, Sidoni A, Bucciarelli E, Darwish S, Ludovini V, Pistola L, Gregorc V, Tonato M.
J Surg Oncol. 2000 May;74(1):53-60.


Author and Co-Author of various textbooks in the field of thoracic neoplasm and mesothelioma.

– Mesotelioma, Eziopatogenesi, presentazione clinica e percorso diagnostico-terapeutico. Ghio D, Gregorc V. Medicina e Diritto 3/2009, Sessione Focus. pg 14-23, Maggioli Editore

– Medicina Interna Sistematica di C. Rugarli, Masson S.p.A anno 2005 –V edizione;
anno 2010 -VI ediizione (ristampa anno 2008, 2009)
 2010 – Contributo in volume (Capitolo o Saggio)
 Belli C, Gregorc V, Lazzari C, Longhini E, Pardi R, Spreafico A, Viganò MG (2010). Tumori del polmone. In: Rugarli. Medicina Interna Sistematica. Sesta edizione.

 2005 –  Contributo in volume (Capitolo o Saggio)
 Longhini E, Pardi R, Gregorc V (2005). Tumori dell’apparato respiratorio. In: Rugarli. Medicina Interna sistematica. Quinta edizione.

– Amianto: responsabilità e risarcimento dei danni, di C. Altomare, M. Cucci, D. Ghio, V. Gregorc, F. Martini, N. Murgia, G. Rossi, Medicina e Diritto, Magioli Editore, 2010

Sanità24ore, 28 agosto 2018

Telemedicina: lo strumento di diagnosi e cura prende corpo anche in Italia

Dall’analisi del fenomeno della migrazione sanitaria, che vede oltre 1 milione di italiani ogni anno spostarsi tra le strutture ospedaliere, prevalentemente dal sud verso il nord, (Fonte: VII Rapporto Rbm-Censis) nasce Ultraspecialisti.com: un portale dedicato alla telesalute, un centro servizi attraverso cui il cittadino dal proprio Pc può richiedere e ottenere un teleconsulto da un medico di alta specialità… Continua a leggere su Sanità24ore

OK Salute e Benessere, 24 luglio 2018

Tumore ai polmoni: tutte le “armi" possibili per sconfiggerlo

Uno, nessuno e centomila: il tumore del polmone sa essere ambiguo come un personaggio pirandelliano, sempre pronto ad assumere forme e identità differenti in ogni paziente e in ogni fase della malattia. Non è facile smascherare questo big killer, che ogni anno in Italia uccide oltre 33mila persone, ma per incastrarlo si stanno preparando identikit genetici sempre più precisi e dettagliati: l’obiettivo è trovare i suoi talloni d’Achille, per colpirli in modo mirato con le strategie terapeutiche più efficaci. «Sono lontani i tempi in cui si parlava solo di carcinoma polmonare a piccole cellule (SCLC) e non a piccole cellule (NSCLC), in base alle caratteristiche morfologiche che il tessuto malato mostrava sotto la lente del microscopio», spiega Vanesa Gregorc, responsabile dell’oncologia toracica dell’Irccs Ospedale San Raffaele di Milano… Continua a leggere su OK Salute e Benessere

Ansa, 21 febbraio 2018

Tumori, al via progetto per il sequenziamento del genoma su 1000 pazienti

… “Abbiamo iniziato dal tumore del polmone – spiega De Maria – perché rappresenta la prima causa di morte tra le neoplasie con 40 mila nuovi casi ogni anno. L’attività è coordinata da Vanesa Gregorc, segretario del Working Group Polmone di ACC e responsabile dell’oncologia toracica dell’IRCCS Ospedale San Raffaele di Milano e si basa sull’utilizzo dell’oncochip creato da ACC Genomics per individuare con precisione e rapidità, grazie a un’ampia profilazione molecolare, le alterazioni genetiche del tumore e curare meglio, tramite l’impiego di nuovi farmaci, ugualmente personalizzati, i pazienti"… Continua a leggere su Ansa

Corriere della sera, 3 giugno 2017

L’oncologa nata in Croazia crea il contatto medico-paziente

Croata con nonni italiani, Vanesa Gregorc ha partecipato al premio MoneyGram «per dimostrare che chi rispetta le regole può farcela in Italia, anche se straniero». E la sua idea vincente lo dimostra. L’oncologa 44enne con una specializzazione nella cura dei tumori polmonari ha dato vita nel 2015 alla piattaforma Ultraspecialisti.com, che mette in contatto medici e pazienti. «Nel lavoro – spiega – mi sono accorta che i malati perdono un sacco di tempo per cercare il dottore giusto. Con il sito che ho creato, invece, possono mandare la documentazione via Internet e ricevere il consulto senza muoversi da casa»… Continua a leggere su il Corriere della Sera

Oncology, settembre 2019
Sequencing algorithms in NSCLC – (ELCC 2019)

OncoInfoTV, 4 giugno 2018
ASCO 2018: KEYNOTE 001 sorprende ancora

Alleanza Contro il Cancro, 19 febbraio 2018
Tumore del polmone, così combattiamo il big killer

Sanofi Vivatech Paris, 15-17 giugno 2017
Le startup della salute a VivaTechnology con Sanofi

PharmaStarTV, Maggio 2017
Novità nella terapia del tumore del polmone metastatico

Medica Editoria, Ottobre 2016
Micro-ambiente tumorale

How to apply for an online medical consultation

Register your details in the secure area and choose the doctor according to your disease.

Fill in the medical history form and upload your reports and clinical exams.

Enter your billing information and make the payment.

Within 5 working days you will receive the doctor’s online consultation.